Mount Sinai Hospital: Experimental Cancer Therapy Shows Success In More Than 70 Percent Of Patients In Global Clinical Trials
December 14, 2022
December 14, 2022
NEW YORK, Dec. 14 -- Mount Sinai Hospital issued the following news release:
A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
The therapy, known as a bispecific antibody, binds to both T cells and multiple myeloma cells and directs the T cells--white blood cells that c . . .
A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
The therapy, known as a bispecific antibody, binds to both T cells and multiple myeloma cells and directs the T cells--white blood cells that c . . .